LinkGevity’s Dr Carina Kern and Serena Kern-Libera discuss new approach to age-related disease

LinkGevity co-founders Dr Carina Kern and Serena Kern-Libera have joined the Beyond Longevity podcast to discuss the science behind the company’s approach to age-related disease and the development of its Anti-Necrotic™ drug candidate, LINK-001.

In conversation with host Daphna Stern, the sisters discuss the idea that conditions such as kidney disease, cardiovascular disease and neurodegenerative disease may share key underlying mechanisms of cellular damage, and how targeting these common mechanisms could provide a new approach to treating age-related disease.

The scientific thinking behind this approach builds on Dr Carina Kern’s Blueprint Theory of Ageing, which examines the interconnected biological processes that drive cellular and tissue degeneration with age.

The discussion explores necrosis, uncontrolled cell death, and LinkGevity’s work in targeting this process to help protect cells and tissues from degeneration. 

Listen to the full Beyond Longevity conversation: https://open.spotify.com/episode/1ekrrZPeMo3sexW2s5rRcJ?si=v_lReWuZRfqnnwkmj-vFeA